NICE recommends against Xolair

The U.K.'s NICE issued a final appraisal determination (FAD) recommending against the use of Xolair omalizumab from Novartis AG (NYSE:NVS; SIX:NOVN) to treat severe persistent asthma in children aged six to 11 years. The FAD reiterates a preliminary appraisal issued in June. The recombinant humanized mAb against IgE is approved as add-on therapy to improve asthma control in patients with severe persistent allergic asthma in patients six and older. ...